Current Treatment of 1L Hodgkin Lymphoma

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

FDA Approval of E7777 (Denileukin Diftitox) for R/R CTCL - Summary o…

Yale Cancer Center

F. Foss

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

ASCO® 2024 Summary: "Treatment of Relapsed HL - Updated Options in L…

2024 ASCO® Annual Meeting Insights Hub

P. Johnson

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Treatment Updates and Management of Hodgkin Lymphoma

Integrity CE

A. Niu, D. Wallace, M. Cortese

Emerging and Current Treatment for Hodgkin Lymphoma in 2024

Indy Hematology Review

S. Ansell

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL…

Total Health

M. Rotta

Summary of Recent Updates in Advanced Hodgkin Lymphoma

SOHO Brazil 2024

C. Moskowitz

EHA 2024 Insights: Treatment of Advanced Stage, High-Risk Hodgkin's …

Insights from 2024 EHA Annual Meeting

M. Salamoon

Summary of Recent Updates in R/R HL

SOHO Brazil 2024

C. Moskowitz

2024 Updates in the Management of DLBCL, FL, and HL

UNC Lineberger Comprehensive Cancer Center

A. Beaven

Overview of Current and Future Management of CTCL

UChicago Medicine

N. Mehta-Shah

Identifying Patients Who Benefit the Most From Radiation in Hodgkin …

UChicago Medicine

C. Pinnix

ASCO® 2024 Summary: "Treatment Considerations for Challenging Popula…

2024 ASCO® Annual Meeting Insights Hub

C. Burton

Caring for Patients With Lymphoma: Using Guidelines to Improve Quali…

Yale Cancer Center

S. Huntington, E. Winer

Treating Fibrosis and Inflammation in GvHD

Pooja Khandelwal

Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…

City of Hope

I. Amanam